NervGen Pharma Appoints Dr. Adam Rogers as Permanent CEO, Grants Substantial Equity Package

summarizeSummary

NervGen Pharma Corp. has formally appointed Dr. Adam Rogers as its Chief Executive Officer and President, a role he previously held on an interim basis, accompanied by a significant equity compensation package.

check_boxKey Events

• Permanent CEO Appointment

  Dr. Adam Rogers, previously Interim CEO since July 2025, has been formally appointed as Chief Executive Officer and President, effective February 9, 2026. He will also continue as Chairperson of the Board.

• Executive Compensation Details

  Dr. Rogers will receive an annualized base salary of $350,000 and is eligible for an annual incentive bonus of up to 30% of his base salary.

• Substantial Equity Grant

  The Board granted Dr. Rogers 717,891 time-based stock options, 1,146,108 performance-based stock options, 37,784 fully vested common shares, and 617,135 performance-based restricted stock units, totaling over 2.5 million potential shares.

auto_awesomeAnalysis

This 6-K filing formalizes the leadership of NervGen Pharma Corp. by appointing Dr. Adam Rogers as the permanent Chief Executive Officer and President, a role he previously held on an interim basis since July 2025. This appointment provides stability and clear direction for the company. The compensation package includes a base salary of $350,000 and substantial equity awards, including over 2.5 million stock options and restricted stock units. This significant equity grant aims to align Dr. Rogers' incentives with long-term shareholder value, though it also implies future dilution. His extensive background as a board-certified physician and biotech entrepreneur, including co-founding Hemera Biosciences, is a positive for the company's strategic direction in life sciences.